Orthomimetics Limited, the UK-Based Regenerative Medicine Company, has
Received CE Mark Approval for Chondromimetic, its Flagship Product for
the Repair of Articular Cartilage and Bone
CAMBRIDGE, England, Jan. 14 /CNW/ - This approval enables the company to
market its line of bioresorbable implants for bone and/or soft tissue repair
in the EU. Orthomimetics' family of products was developed during a
groundbreaking collaboration between the University of Cambridge and the
Massachusetts Institute of Technology.
Chondromimetic is a novel off-the-shelf implant that helps to support the
repair of defects involving both articular cartilage and bone - defects that
can result from sports injuries, surgical intervention and other trauma.
Articular cartilage damage and subsequent degeneration of the underlying bone
are known to be a major cause of arthritis in young individuals.
CE-mark approval enables the company to market Chondromimetic in Europe,
and comes earlier than originally forecast at the time of the company's
December 2006 Series A financing. Orthomimetics will immediately launch a
comprehensive post-market clinical-trial program for Chondromimetic, and is
currently negotiating distribution agreements for key European territories.
The company will pursue additional approvals in other global territories
Commenting on the CE Mark approval, Dr Andrew Lynn, CEO of Orthomimetics,
"Orthomimetics is extremely pleased to be able to make Chondromimetic
available for surgeons and patients in Europe. This approval is the result of
a tremendous amount of hard work on the part of our surgeon advisors,
scientific collaborators, and - most of all - our professional, dedicated
team. We look forward to making Chondromimetic a clinical and commercial
Orthomimetics Limited is a medical technology company that specialises in
the design, development, and manufacture of regenerative medical implants and
minimally invasive delivery systems for the treatment of sports injuries,
trauma and other conditions that affect knees, ankles and other articular
joints. Formed in 2005 as the first spin-out venture from the Cambridge-MIT
Institute, the company is bringing to market a line of medical device products
designed to improve the treatment outcome of first-line surgical procedures
for the regenerative repair of articular cartilage, meniscus, ligament and
tendon injuries using natural biomaterials. These products are engineered to
be compatible with existing surgical techniques and to work in combination
with emerging cell- and biologics-based products.
For further information on Orthomimetics please go to our website:
http://www.orthomimetics.com or contact Katherine Webster:
For further information:
For further information: Katherine Webster, firstname.lastname@example.org,